Free Newsletter
ALSO NOTED: Sanofi sues to fight off Uroxatral imitators; Watson gets OK for generic AccuNeb
> Sanofi Aventis sued two generics makers--Teva Pharmaceuticals and Barr Laboratories--for infringing its patents on the prostate cancer drug Uroxatral. Report
> Watson Pharmaceuticals got the FDA nod for its generic form of the asthma medication AccuNeb. Report
> Sanofi Pasteur is scouting India, among other countries, for possible locations for a global manufacturing base, the Economic Times reports. Report
> AstraZeneca is poised to open an Israeli office and is seeking a local general manager there. Report
And Finally... Don't count on snagging your daily meds from a pharma facility. The thieves who got out of Genentech with human growth hormone are exceptions to the high-security rule--so much so that one expert likened a drug-company theft to stealing gold from Fort Knox. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: